fentonium and Substance-Withdrawal-Syndrome

This study has tested whether phentonium bromide, a quaternary ammonium anti-muscarinic agent, could reverse the signs of precipitated opioid withdrawal. Rats were treated with either saline or morphine for 4 days, after which half the rats received naloxone and half saline. Each animal also received one of four doses of phentonium bromide (0, 1, 3 and 9 mg kg(-1), i.p.). Administration of phentonium bromide in rats receiving naloxone after chronic morphine treatment reduced the intensity of withdrawal signs such as increased defecation or micturition, salivation and wet-dog shakes, and elevated the nociceptive threshold values. The effects of administration of phentonium bromide might result from its anti-muscarinic activity interfering peripherally with the mechanisms involved in the regulation of the withdrawal symptoms. The use of this drug is thus suggested as a possible means of controlling some of the signs observed during the acute phase of opioid withdrawal in heroin addicts.

Topics: Analgesics, Opioid; Analysis of Variance; Animals; Atropine Derivatives; Body Temperature; Defecation; Male; Molecular Structure; Morphine; Naloxone; Narcotic Antagonists; Parasympatholytics; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Substance Withdrawal Syndrome; Urination